National Specialised Hospital For Active Treatment Of Haematological Diseases — Clinical Trial Site

7 Registered trials

2 Currently recruiting

Organisation

National Specialised Hospital For Active Treatment Of Haematological Diseases

Location

Sofia, Bulgaria

Identifier

ORG-100023865

Address

Ul.plovdivsko Pole 6, 1756, Bulgaria

Departments

Clinic of clinical hematology
Department of Hematopoietic Stem Cell Transplantation
First department of Clinical Hematology
First Department of Clinical Hematology at Clinic of Clinical Hematology
N/A

Clinical trials at this site (7)

Search interface

A study to assess the Efficacy and Safety of Efgartigimod IV in Adult Participants with Primary Immune Thrombocytopenia Recruiting

2024-515451-38-00 Primary Immune thrombocytopenia (ITP) 5 2025-02-27
This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi… Recruiting

2023-505277-32-00 Diffuse Large B-Cell Lymphoma (DLBCL) 5 2023-01-26
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Capsules Compared to Intravenously (IV) Infused Rituximab Plus IV Infu… Ended

2024-510965-41-00 Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymph 5 2024-09-03
A study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T) Ended

2024-512747-23-00 Transfusion-Dependent Alpha- or Beta-Thalassemia 5 2024-07-30
A study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Non Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE) Ended

2024-512745-16-00 Non–Transfusion-Dependent Alpha- or Beta-Thalassemia 5 2022-04-13
Study to test the safety and how well patients with severe hemophilia A respond to treatment with BAY 2599023 (DTX 201), a drug therapy that… Ended

2023-505827-29-00 Hemophilia A 7 2018-10-30
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENT… Ended

2023-510446-24-00 Cancer cachexia 4 2023-05-30